161 related articles for article (PubMed ID: 38811157)
21. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges.
Fairman K; Li M; Ning B; Lumen A
Biochem Pharmacol; 2021 Jul; 189():114468. PubMed ID: 33577889
[TBL] [Abstract][Full Text] [Related]
22. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling.
Chou WC; Lin Z
Toxicol Sci; 2023 Jan; 191(1):1-14. PubMed ID: 36156156
[TBL] [Abstract][Full Text] [Related]
23. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.
Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Unadkat JD
Br J Clin Pharmacol; 2014 Mar; 77(3):554-70. PubMed ID: 23834474
[TBL] [Abstract][Full Text] [Related]
24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
25. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
Li M; Zou P; Tyner K; Lee S
AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
[TBL] [Abstract][Full Text] [Related]
26. Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine.
Zheng L; Yang H; Dallmann A; Jiang X; Wang L; Hu W
Front Pharmacol; 2021; 12():793346. PubMed ID: 35126130
[TBL] [Abstract][Full Text] [Related]
27. When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.
Sychterz C; Galetin A; Taskar KS
Biopharm Drug Dispos; 2021 Apr; 42(4):160-177. PubMed ID: 33759451
[TBL] [Abstract][Full Text] [Related]
28. Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations.
Chothe PP; Arya V; Prasad B; Ramsden D; Taskar K
Drug Metab Dispos; 2023 Dec; 51(12):1547-1550. PubMed ID: 37775331
[TBL] [Abstract][Full Text] [Related]
29. Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.
Ke AB; Greupink R; Abduljalil K
CPT Pharmacometrics Syst Pharmacol; 2018 Feb; 7(2):103-110. PubMed ID: 29349870
[TBL] [Abstract][Full Text] [Related]
30.
Foti RS
Drug Metab Dispos; 2024 Jan; ():. PubMed ID: 38290748
[TBL] [Abstract][Full Text] [Related]
31.
Zhang CX; Arnold SLM
Drug Metab Dispos; 2023 Sep; ():. PubMed ID: 37714715
[TBL] [Abstract][Full Text] [Related]
32. PBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia.
Macente J; Nauwelaerts N; Russo FM; Deprest J; Allegaert K; Lammens B; Hernandes Bonan R; Turner JM; Kumar S; Diniz A; Martins FS; Annaert P
Front Pharmacol; 2023; 14():1068153. PubMed ID: 36998614
[TBL] [Abstract][Full Text] [Related]
33. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.
Moss DM; Siccardi M
Br J Pharmacol; 2014 Sep; 171(17):3963-79. PubMed ID: 24467481
[TBL] [Abstract][Full Text] [Related]
34. Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models.
Chaphekar N; Dodeja P; Shaik IH; Caritis S; Venkataramanan R
Front Pediatr; 2021; 9():733823. PubMed ID: 34805038
[TBL] [Abstract][Full Text] [Related]
35. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
[TBL] [Abstract][Full Text] [Related]
36. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.
Huang W; Nakano M; Sager J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2017 Nov; 45(11):1156-1165. PubMed ID: 28860113
[TBL] [Abstract][Full Text] [Related]
37. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
38. Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics.
Yang X; Grimstein M; Pressly M; Fletcher EP; Shord S; Leong R
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140068
[TBL] [Abstract][Full Text] [Related]
39. Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.
Yang Y; Zhang X
Methods Mol Biol; 2022; 2486():57-69. PubMed ID: 35437718
[TBL] [Abstract][Full Text] [Related]
40. Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.
Alqahtani S; Kaddoumi A
PLoS One; 2015; 10(10):e0139762. PubMed ID: 26431339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
